Kymab: More mAb diversity

Wellcome backing Kymab's Kymouse to create diverse human antibodies

Kymab Ltd. is developing its Kymouse transgenic mouse platform to generate a greater repertoire of human mAbs than it says can be done with competing technologies. With the Wellcome Trust backing the newco, management plans to build an internal therapeutic pipeline and partner the technology on a non-exclusive basis.

The diversity of mAbs generated by a transgenic mouse platform is determined by three key factors, according to Kymab Chairman and CEO Andrew Sandham.

The first is the size of the human gene set used to encode the mAb variable region, which consists

Read the full 907 word article

How to gain access

Continue reading with a
two-week free trial.